Diferencia entre revisiones de «Ipratropium»
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
|||
| Línea 40: | Línea 40: | ||
*Excretion: Fecal and Renal | *Excretion: Fecal and Renal | ||
*Mechanism of Action: Cholinergic antagonist of acetylcholine at the cholinergic receptors, causing dilatation of bronchial smooth muscle and decreased serous and seromucous glands secretion. | *Mechanism of Action: Cholinergic antagonist of acetylcholine at the cholinergic receptors, causing dilatation of bronchial smooth muscle and decreased serous and seromucous glands secretion. | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Ipratropium]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=broadtable | |||
|headers=plain | |||
|link=subject | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
Revisión del 16:42 20 mar 2026
General
- Type: Anticholinergic Agent
- Dosage Forms: Oral inhalation
- Common Trade Names: Atrovent
Adult Dosing
Asthma: 0.5mg Nebulized q20min, up to 3 doses
COPD: 0.5mg Nebulized q20mins, up to 3 doses
Pediatric Dosing
- Children ≤5 years: 0.25mg Neb q20mins, up to 3 doses
- Children ≤12 years: 0.25-0.5mg Neb q20mins, up to 3 doses
- Children >12 years: Refer to adult dosing
Special Populations
- Pregnancy Rating: B
- Lactation risk categories: L3
- Renal Dosing - none
- Hepatic Dosing - none
Contraindications
- Allergy to anticholenergics (Atropine, Ipatropium)
- Not to be used as sole rescue agent in acute exacerbation
Adverse Reactions
Serious
- Death
Common
- Urinary retention
- Increased intraocular pressure
- Bitter taste in mouth
- Dry throat/Cough
- Nasal dryness
Pharmacology
- Half-life: 2-5hrs
- Metabolism: Possible ester hydrolysis
- Excretion: Fecal and Renal
- Mechanism of Action: Cholinergic antagonist of acetylcholine at the cholinergic receptors, causing dilatation of bronchial smooth muscle and decreased serous and seromucous glands secretion.
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population | |
|---|---|---|---|---|---|
| Acute asthma exacerbation#Ipratropium Anticholinergic adjunct (acute setting only) Adult | Acute asthma exacerbation | 0.25-0.5 mg nebulized q20min x2-3 doses | Anticholinergic adjunct (acute setting only) | Nebulized | Adult |
| Acute asthma exacerbation (peds)#Ipratropium Adjunctive anticholinergic; reduces admissions Pediatric | Acute asthma exacerbation (peds) | 0.25-0.5mg q20min x3 (with first 3 albuterol doses) | Adjunctive anticholinergic; reduces admissions | Nebulized | Pediatric |